Pfizer entered a research collaboration with Gordian Bio to apply Gordian’s in vivo mosaic screening platform to prioritize obesity targets directly in visceral adipose tissue. The collaboration will screen hundreds of gene targets in living tissue to capture physiologic context that ex vivo models miss. Gordian said the partnership will generate decision‑ready target scores and mechanistic insights for visceral fat biology, supporting Pfizer’s obesity discovery efforts. Companies called this an example of platform‑first partnering aimed at translating complex tissue biology into prioritised therapeutic hypotheses.